A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer

The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in people with brain metastases from their cancer.

开始日期2014-10-09

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT02133846

/ Completed临床1期IIT

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT), corticobasal syndrome (CBS; also called corticobasal degeneration, CBD) or progressive supranuclear palsy (PSP).

开始日期2014-05-01

申办/合作机构

The University of California, San Francisco

[+2]

NCT02047214

/ Terminated临床2期

Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen

The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide (TMZ) therapy and that has progressed following prior bevacizumab therapy.

开始日期2014-01-01

申办/合作机构

Cortice Biosciences, Inc.

100 项与 ARC-100 相关的临床结果

登录后查看更多信息

100 项与 ARC-100 相关的转化医学

登录后查看更多信息

100 项与 ARC-100 相关的专利（医药）

登录后查看更多信息

项与 ARC-100 相关的文献（医药）

2024-01-01·Neuro-oncology advances

Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma

Article

作者: Benkers, Tara ; Singer, Samuel ; Duic, Paul J ; Hsu, Sigmund ; Rao, Mayank ; Goldlust, Samuel A ; Nabors, Louis B ; Silberman, Sandra L ; Mohile, Nimish ; Cappello, Lori ; Farmer, George

Abstract:

Background:

Recurrent glioblastoma (rGBM) has limited treatment options. This phase 1 protocol was designed to study the safety and preliminary efficacy of TPI 287, a central nervous system penetrant microtubule stabilizer, in combination with bevacizumab (BEV) for the treatment of rGBM.

Methods:

GBM patients with up to 2 prior relapses without prior exposure to anti-angiogenic therapy were eligible. A standard 3 + 3 design was utilized to determine the maximum tolerated dose (MTD) of TPI 287. Cohorts received TPI 287 at 140–220 mg/m2 every 3 weeks and BEV 10 mg/kg every 2 weeks during 6-week cycles. An MRI was performed after each cycle, and treatment continued until progression as determined via response assessment in neuro-oncology criteria.

Results:

Twenty-four patients were enrolled at 6 centers. Treatment was generally well tolerated. Fatigue, myelosuppression, and peripheral neuropathy were the most common treatment emergent adverse events. Dose-limiting toxicity was not observed, thus the MTD was not determined. Twenty-three patients were evaluable for median and 6-month progression-free survival, which were 5.5 months (mo) and 40%, respectively. Median and 12-month overall survival were 13.4 mo and 64%, respectively. The optimal phase 2 dose was determined to be 200 mg/m2.

Conclusions:

TPI 287 can be safely combined with BEV for the treatment of rGBM and preliminary efficacy supports further investigation of this combination.

2023-02-01·Cancer chemotherapy and pharmacology

The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo

Article

作者: Lehman, Norman L ; Teer, Landon ; Hey, Andrew J ; Williams, Brian J ; Kakar, Aastha ; Schier, Leslie M ; Chen, Joseph ; Sak, Müge ; Al-Kawaaz, Mustafa N G ; Wilson, Megan J ; Zumbar, Cory T

INTRODUCTION:

Glioblastoma (GBM) has a very poor prognosis despite current treatment. We previously found cytotoxic synergy between the AURKA inhibitor alisertib and the CNS-penetrating taxane TPI 287 against GBM tumor cells in vitro.

METHODS:

We used an orthotopic human GBM xenograft mouse model to test if TPI 287 potentiates alisertib in vivo. Western blotting, immunohistochemistry, siRNA knockdown, annexin V binding, and 3-dimensional Matrigel invasion assays were used to investigate potential mechanisms of alisertib and TPI 287 treatment interactions.

RESULTS:

Alisertib + TPI 287 combination therapy significantly prolonged animal survival compared to vehicle (p = 0.011), but only marginally compared to alisertib alone. Alisertib, TPI 287, and combined alisertib + TPI 287 reduced animal tumor volume compared to vehicle-treated controls. This was statistically significant for the combination therapy at 4 weeks (p < 0.0001). Alisertib + TPI 287 treatment decreased anti-apoptotic Bcl-2 protein levels in vivo and in vitro. Expression of the pro-apoptotic protein Bak was significantly increased by combination treatment (p < 0.0001). Pro-apoptotic Bim and Bak knockdown by siRNA decreased apoptosis by alisertib + TPI 287 in GB9, GB30, and U87 cells (p = 0.0005 to 0.0381). Although alisertib and TPI 287 significantly reduced GBM cell invasion (p < 0.0001), their combination was no more effective than TPI 287 alone.

CONCLUSIONS:

Results suggest that apoptosis is the dominant mechanism of potentiation of GBM growth inhibition by alisertib + TPI 287, in part through effects on Bcl-2 family proteins, providing a rationale for further laboratory testing of an AURKA inhibitor plus TPI 287 as a potential therapy against GBM.

2020-02-01·JAMA neurology1区 · 医学

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome

1区 · 医学

Article

作者: Geldmacher, David S. ; Koestler, Mary ; Hare, Emma ; Powers, Ryan ; Shamloo, Merhdad ; Jung, Joo In ; Rosen, Howard J. ; Tsai, Richard M. ; Chuu, Emmeline L. ; Luong, Phi N. ; Mumford, Paige ; Rabinovici, Gil D. ; Wolf, Amy ; Miller, Zachary ; Boxer, Adam L. ; Ljubenkov, Peter A. ; Natelson-Love, Marissa ; Miller, Bruce L. ; Fagan, Anne M. ; Cobigo, Yann ; Wang, Ping ; Rojas, Julio C. ; Roberson, Erik D. ; McKinley, Emily C. ; Brown, Jesse A.

Importance:

Basket-design clinical trials that allow investigation of treatment effects on different clinical syndromes that share the same molecular pathophysiology have not previously been attempted in neurodegenerative disease.

Objective:

To assess the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 (abeotaxane) in Alzheimer disease (AD) or the 4-repeat tauopathies (4RT) progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).

Design, Setting, and Participants:

Two parallel-design, double-blind, placebo-controlled phase 1 randomized clinical trials in AD and 4RT were conducted from December 20, 2013, through May 4, 2017, at the University of California, San Francisco, and University of Alabama at Birmingham. A total of 94 patients with clinically diagnosed AD (n = 39) and 4RT (n = 55) were screened; of these, 3 refused to participate, and 10 with AD and 11 with 4RT did not meet inclusion criteria. A total of 29 patients with AD, 14 with PSP, and 30 with β-amyloid-negative CBS (determined on positron emission tomography findings) were enrolled. Data were analyzed from December 20, 2013, through May 4, 2017, based on modified intention to treat.

Interventions:

Randomization was 8:3 drug to placebo in 3 sequential dose cohorts receiving 2.0, 6.3, or 20.0 mg/m2 of intravenous TPI-287 once every 3 weeks for 9 weeks, with an optional 6-week open-label extension.

Main Outcomes and Measures:

Primary end points were safety and tolerability (maximal tolerated dose) of TPI-287. Secondary and exploratory end points included TPI-287 levels in cerebrospinal fluid (CSF) and changes on biomarker, clinical, and neuropsychology measures.

Results:

A total of 68 participants (38 men [56%]; median age, 65 [range, 50-85] years) were included in the modified intention-to-treat analysis, of whom 26 had AD (14 women [54%]; median age, 63 [range, 50-76] years), and 42 had 4RT (16 women [38%]; median age, 69 [range, 54-83] years). Three severe anaphylactoid reactions occurred in TPI-287-treated patients with AD, whereas none were seen in patients with 4RT, leading to a maximal tolerated dose of 6.3 mg/m2 for AD and 20.0 mg/m2 for 4RT. More falls (3 in the placebo group vs 11 in the TPI-287 group) and a dose-related worsening of dementia symptoms (mean [SD] in the CDR plus NACC FTLD-SB [Clinical Dementia Rating scale sum of boxes with frontotemporal dementia measures], 0.5 [1.8] in the placebo group vs 0.7 [1.6] in the TPI-287 group; median difference, 1.5 [95% CI, 0-2.5]; P = .03) were seen in patients with 4RT. Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3-like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], -8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, -14.6 [95% CI, -30.0 to 0.2] ng/mL; P = .048, Mann-Whitney test).

Conclusions and Relevance:

In this randomized clinical trial, TPI-287 was less tolerated in patients with AD than in those with 4RT owing to the presence of anaphylactoid reactions. The ability to reveal different tau therapeutic effects in various tauopathy syndromes suggests that basket trials are a valuable approach to tau therapeutic early clinical development.

Trial Registration:

ClinicalTrials.gov identifiers: NCT019666666 and NCT02133846.

项与 ARC-100 相关的新闻（医药）

2026-08-12

·BioSpace

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2026 and provided an update on the corporate strategy the company introduced in March 2026. "We are moving with speed and discipline to transform this company," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "In the second quarter, we significantly strengthened our balance sheet and added new expertise to our Board to enable us to build a differentiated, high-value pipeline of innovative therapies. We are executing with urgency and are confident that the actions we've taken this year strengthen CNS Pharmaceuticals ability to create meaningful value going forward." Strategic and Corporate Highlights ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); New corporate strategy in motion. Since announcing its strategic pivot in March 2026 beyond a singular focus on glioblastoma multiforme, the Company has been leveraging its executive team's multi-functional experience across high-value therapeutic areas. As previously stated, the Company expects to in-license or acquire one or more assets by year end 2026. Oversubscribed $22.5 million financing closed. On May 5, 2026, the Company closed a private placement with institutional investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners, generating approximately $22.5 million in gross proceeds ($20.7 million net), significantly reinforcing the Company's capital and shareholder base in support of its new strategy. Board strengthened with dealmaking depth. The Company appointed Michal Fisher, a life sciences executive with a track record in business development, licensing and capital formation, including prior leadership roles in strategic alliances and corporate development to its Board of Directors in May 2026. Legacy programs advancing toward closure. The Company's global clinical trial of Berubicin for glioblastoma is complete. The Company is now focused on closing out the study while pursuing out-licensing discussions for both Berubicin and TPI 287. Since announcing its new corporate strategy in March 2026, the Company has focused on leveraging the experience of its leadership team to identify promising development-stage therapeutic assets that align with its strategy of building a diversified pipeline targeting serious diseases. Management is actively evaluating business development opportunities while maintaining financial discipline and preserving capital for future growth initiatives. "This quarter reflects the deliberate work of resetting CNS Pharmaceuticals for its next chapter," said Steve O'Loughlin, Chief Financial Officer. "With a fortified balance sheet, extended capital runway, and new shareholder base comprised of biotech focused institutional investors, we are well positioned to execute our strategy with an enhanced ability to transact." Second Quarter 2026 Financial Results Cash and cash equivalents were approximately $20.0 million as of June 30, 2026, compared to $7.2 million as of December 31, 2025. The increase primarily reflects the Company's previously announced private placement financing completed in May 2026. The Company believes its existing cash resources are sufficient to fund planned operations beyond the next twelve months as it continues executing its strategic business development initiatives. Research and development expenses were approximately $1.2 million for the second quarter of 2026, compared to $1.2 million for the same period in 2025. Research and development expenses included activities related to completing and closing out the Berubicin clinical trial, as enrollment and patient treatment have been completed. Future research and development expenses will depend on the timing and nature of any assets the Company acquires or licenses and the associated development activities. General and administrative expenses were approximately $1.5 million for the second quarter of 2026, compared to $1.2 million for the same period in 2025. The increase was primarily attributable to higher headcount-related expenses, partially offset by lower professional services costs. Net loss for the second quarter of 2026 was approximately $2.6 million, or $0.37 per basic and diluted share, compared to a net loss of approximately $2.4 million, or $6.42 per basic and diluted share, for the second quarter of 2025. As of August 14, 2025, the Company had 1,461,449 common shares of stock outstanding and 10,604,928 shares fully diluted including pre-funded warrants that were issued in its May 2026 financing. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders. For more information, please visit , and connect with the Company on X and LinkedIn . Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com Business Development Contact CNS Pharmaceuticals, Inc. Dylan Wenke, Chief Business Officer dwenke@cnspharma.com SOURCE: CNS Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

财报高管变更

2026-05-14

·BioSpace

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287 New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting the Company's ongoing strategic transformation and execution progress. The first quarter of 2026 marked the beginning of a significant strategic shift for CNS Pharmaceuticals, including the appointment of a new Chief Executive Officer and executive leadership team, the launch of a new corporate strategy, the repositioning of the Company toward an acquisition-driven growth strategy focused on differentiated clinical-stage assets in neurology and oncology and the decision to seek out-licensing opportunities for its legacy glioblastoma multiforme programs, Berubicin and TPI-287. Subsequent to quarter end, CNS Pharmaceuticals completed a $22.5 million private placement with participation from several leading institutional healthcare investors. The proceeds from the private placement, together with existing cash, are intended to enable CNS Pharmaceuticals to identify, acquire, and advance differentiated assets with clear development and regulatory pathways that have clear inflection catalysts and the potential for near-term value creation. "We believe CNS Pharmaceuticals has entered a transformational new phase defined by strategic clarity, financial strength and disciplined execution," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "Over the past several months, we have rebuilt the foundation of the Company by assemblinga highly experienced executive team, completed a rigorous strategic review, strengthened our balance sheet through an oversubscribed financing, initiated an aggressive search for differentiated clinical-stage assets capable of generating meaningful near-term catalysts and long-term shareholder value, and advanced discussions to out-license our legacy glioblastoma multiforme programs, Berubicin and TPI-287." Mr. Levin continued, "The current biotechnology environment continues to create compelling acquisition opportunities, particularly for companies with capital, operational experience and strategic focus. We believe CNS Pharmaceuticals is now positioned to capitalize on this environment as we rapidly work to build and diversify our pipeline with high-value programs that have clear development pathways and the potential to drive substantial value creation." Summary of Financial Results for the First Quarter 2026 General and administrative expense was approximately $1,431,000 for the three months ended March 31, 2026 compared to approximately $1,095,000 for the comparable period in 2025. The increase in general and administrative expense was primarily attributable to increased professional expenses related to the Company's strategic review that was conducted in collaboration with a leading life science focused advisory firm and placement services related to the Company's new executive leadership team. Research and development expense was approximately $3,544,000 for the three months ended March 31, 2026 compared to approximately $3,243,000 for the comparable period in 2025. The change in research and development expense during the period is primarily attributable to an increase in placement services and headcount expense. The net loss for the three months ended March 31, 2026 was approximately $4,936,000 compared to approximately $4,301,000 for the comparable period in 2025. The change in net loss is primarily attributable to increased research and development costs and an increase in professional expenses. Cash and cash equivalents were $2,951,000 as of March 31, 2026. The cash balance on March 31, 2026 does not account for the gross proceeds from the $22.5 million private placement closed on May 5, 2026. The Company expects these proceeds, together with existing cash resources, to fund operations beyond twelve months. About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders. For more information, please visit , and connect with the Company on X and LinkedIn . Forward-Looking Statements Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the expected gross proceeds and closing of the private placement, the Company's intended use of proceeds from the private placement together with existing cash, the Company's pipeline prioritization and strategic development, the anticipated contributions of the new management team to the Company's growth, expectations regarding clinical development and regulatory strategy, the Company's ability to deliver meaningful value to patients and shareholders, and the Company's plans to explore out-licensing or strategic sales of legacy assets. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law. CONTACTS: Investor Relations Contact JTC Team, LLC Jenene Thomas 908.824.0775 CNSP@jtcir.com Business Development Contact CNS Pharmaceuticals, Inc. Dylan Wenke, Chief Business Officer dwenke@cnspharma.com SOURCE: CNS Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

财报高管变更并购

2026-03-11

·FierceBiotech

CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets

CNS Pharmaceuticals\' new approach is to bring in preclinical or clinical candidates with “defined value inflection points.”\n With a fresh leadership team settling in, CNS Pharmaceuticals is wiping its pipeline clean as it hunts for a new lead asset.After tapping a consulting firm for advice, the Houston-based biotech has elected to offload its glioblastoma candidates berubicin and TPI 287, the company announced in a March 11 release. CNS is now looking for partners that can take these assets off its hands while the company shops for promising new prospects in neurology and oncology.A phase 2 trial of berubicin in recurrent glioblastoma multiforme will continue through its expected completion in July, a spokesperson for CNS told Fierce Biotech this morning. The company had previously reported that berubicin failed to top fellow chemotherapy lomustine in this trial, though the study wasn’t powered to test for noninferiority.TPI 287, meanwhile, has not yet commenced its next phase of clinical development, according to the spokesperson, who explained that CNS won’t advance the asset any further. The biotech had previously said it planned to launch a phase 2 trial for the molecule, a derivative of the chemotherapy taxane.TPI 287 and berubicin are CNS\' only two assets, the spokesperson confirmed.The strategic pivot doesn’t come with any layoffs, the spokesperson added, and, instead, the new leadership team has “the intent to build and grow the company.”The Texas outfit’s new approach will be to bring in preclinical or clinical candidates with “defined value inflection points” that meet significant unmet medical needs in neurology or oncology, according to the release. “Strategic transformations are a common and often successful approach in biotechnology,” Rami Levin, who took over as CEO of CNS in January, said in the release. “With the right leadership experience and a disciplined, data-driven strategy, companies can transform their pipelines and create substantial value.”Not long after taking the helm, Levin brought on board a new chief financial officer, a chief technology officer, a chief business officer and a chief medical officer. He also wrote a letter to shareholders announcing that he was thoroughly evaluating the company’s pipeline and operations.In its most recent financial disclosure last November, CNS revealed cash reserves of about $9.9 million, which the biotech envisioned funding operations into the second half of this year.

临床2期高管变更财报

100 项与 ARC-100 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性黑色素瘤	临床2期	美国	Cortice Biosciences, Inc.	2013-09-01
复发性神经母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2011-12-01
髓母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2011-12-01
乳腺癌	临床2期	美国	Cortice Biosciences, Inc.	2011-08-16
乳腺癌脑转移	临床2期	美国	Cortice Biosciences, Inc.	2011-08-16
多形性胶质母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2010-04-01
复发性胶质母细胞瘤	临床2期	美国	Cortice Biosciences, Inc.	2010-04-01
不能切除性胰腺癌	临床2期	美国	Cortice Biosciences, Inc.	2007-10-01
不能切除性胰腺癌	临床2期	西班牙	Cortice Biosciences, Inc.	2007-10-01
转移性前列腺癌	临床2期	美国	Cortice Biosciences, Inc.	2007-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) 人工标引	临床1期	阿尔茨海默症 \| 皮质基底节变性 \| 进行性核上性麻痹	68	TPI-287	築鏇壓憲願網觸顧網廠(繭壓廠鹽觸膚淵願觸範) = 願淵繭鏇鏇艱簾鹽網襯壓醖壓積觸觸壓蓋築製 (獵淵夢願淵餘夢壓遞範 ) 更多	积极	2020-02-01
NCT02133846 \| NCT01966666 (Pubmed \| JAMA Neurol) 人工标引	临床1期	阿尔茨海默症 \| 皮质基底节变性 \| 进行性核上性麻痹	68	Placebo	築鏇壓憲願網觸顧網廠(繭壓廠鹽觸膚淵願觸範) = 選壓網選艱蓋遞觸遞廠壓醖壓積觸觸壓蓋築製 (獵淵夢願淵餘夢壓遞範 ) 更多	积极	2020-02-01
NCT01582152 (CTgov)	临床1/2期	复发性胶质母细胞瘤	12	Bevacizumab+TPI (TPI 287 160 mg/m2 + Bevacizumab)	鹽獵構廠廠醖糧構淵顧(鑰範選觸鏇遞鹽糧範醖) = 艱衊衊製遞範衊製鬱蓋築獵簾鬱夢艱鹹糧窪壓 (願獵衊鑰繭積顧夢鏇廠, 鹹鹽獵夢築築製壓衊願 ~ 鏇鑰餘鑰廠選醖鹽範餘) 更多	-	2019-06-05
NCT01582152 (CTgov)	临床1/2期	复发性胶质母细胞瘤	12	Bevacizumab+TPI (TPI 287 140 mg/m2 + Bevacizumab)	鹽獵構廠廠醖糧構淵顧(鑰範選觸鏇遞鹽糧範醖) = 顧積鏇鹽鏇淵夢齋簾膚築獵簾鬱夢艱鹹糧窪壓 (願獵衊鑰繭積顧夢鏇廠, 襯窪鬱鹽遞壓築蓋鹹憲 ~ 簾蓋衊網衊衊餘壓鏇窪) 更多	-	2019-06-05
NCT01332630 (CTgov)	临床2期	乳腺癌脑转移 \| 乳腺癌	24	Dexamethasone+TPI 287+Ranitidine+Benadryl	選鹽積獵選廠積鏇繭鏇 = 餘鏇範糧願願壓選築夢衊襯糧廠餘顧夢艱鬱願 (壓憲艱鬱膚鹽積淵餘壓, 選艱鹽鹽繭糧簾醖鏇艱 ~ 醖憲襯鹹齋糧襯膚鑰艱) 更多	-	2018-07-10
CB-017 (SNO2017)	临床1/2期	复发性胶质母细胞瘤 unmethylated MGMT promoter	-	TPI 287	選鏇觸艱糧繭糧鏇遞齋(顧積獵艱醖淵壓憲淵顧) = 願願觸淵簾遞選襯齋壓窪構壓襯憲繭顧網鬱構 (鏇鹽願糧鑰顧構窪窪獵 ) 更多	积极	2017-11-06
NCT01933815 (ASCO 12017 \| ASCO 22017) 人工标引	临床1/2期	复发性胶质母细胞瘤	24	bevacizumab+TPI 287	鹹築襯窪鹹簾選醖選膚(衊遞鹽艱網淵糧廠蓋構) = 壓鹹夢顧淵範範壓鹽夢製網餘範獵簾窪選獵網 (構衊築艱窪繭範網積製 ) 更多	积极	2017-06-05
NCT01067066 (Pubmed \| Melanoma Res) 人工标引	临床1期	转移性黑色素瘤	21	temozolomide+TPI 287	蓋願簾艱糧糧壓醖糧繭(網獵襯製繭製襯繭繭醖) = neuropathy and six patients experienced grade III neuropathy 糧積簾壓糧蓋範艱糧構 (鏇繭遞製網顧鬱艱願鏇 ) 更多	积极	2016-12-01
SNO2016	临床1/2期	复发性胶质母细胞瘤	-	TPI 287	繭範簾夢簾鏇鏇範窪夢(築廠夢築衊醖窪選餘窪) = myelosuppression (n=3) was the only drug-related grade 3/4 adverse event 獵簾觸窪鏇網鹽醖艱襯 (襯鬱壓夢窪餘獵願艱憲 )	积极	2016-11-07
NCT01113463 (CTgov)	临床2期	多形性胶质母细胞瘤 \| 复发性胶质母细胞瘤	17	TPI 287	觸糧鑰廠膚遞簾淵願鏇 = 簾齋齋憲糧選鏇繭壓襯糧廠鑰鬱壓選襯壓醖壓 (觸壓夢鬱糧願網糧蓋觸, 範壓鏇鏇網觸製構餘衊 ~ 壓齋膚廠醖壓獵範選獵) 更多	-	2016-10-31
NCT00867568 (CTgov)	临床1期	复发性髓母细胞瘤 \| 神经母细胞瘤 \| 髓母细胞瘤	18	TPI 287	構廠觸範簾糧繭鹽廠齋 = 鏇鏇膚積淵積鹽餘鏇繭夢遞獵製淵蓋壓築顧鏇 (蓋齋膚窪製淵鏇憲範簾, 壓夢獵構憲衊壓網鏇廠 ~ 積壓選餘壓襯築憲壓憲) 更多	-	2016-10-28
NCT01505608 (CTgov)	临床1/2期	复发性神经母细胞瘤 \| 神经母细胞瘤	14	Temozolomide+Irinotecan (Arm A- Temozolomide and Irinotecan)	壓餘範積憲網衊築衊繭 = 積蓋網襯簾積鹽願構糧構餘齋選鹽鹹範製蓋廠 (觸醖獵築鏇襯範齋築艱, 醖窪築鹹淵壓衊鏇鏇窪 ~ 網艱廠鹽鏇窪簾膚淵遞) 更多	-	2016-10-28
NCT01505608 (CTgov)	临床1/2期	复发性神经母细胞瘤 \| 神经母细胞瘤	14	Temozolomide+TPI 287+Irinotecan (Arm B- Temozolomide/Irinotecan + TPI 287)	築鹹繭製壓願顧觸獵齋 = 遞鏇窪網窪壓鏇築築醖鏇壓遞淵夢憲糧積齋鑰 (製衊構艱夢鑰範齋網遞, 獵壓齋顧簾選鑰齋鑰艱 ~ 構網膚鹹糧夢鑰願廠鏇)	-	2016-10-28